New findings from groundbreaking study shows extended delay in onset of type 1 diabetes

Data presented today at the ADA 80th Scientific Sessions by Emily Sims, M.D. details the Phase 2 Teplizumab Prevention Study Clinical Trial findings that showed a two-week course of teplizumab delayed the onset of clinical T1D by three years.